Chymostatin
Chymotrypsin-like serine protease inhibitor / A potent, competitive, slow-binding inhibitor of α-, β-, γ-, δ-chymotrypsin, papain and cathepsins B/G (chymotryptase-like serine proteases)1, Ki=9.36 and 13.1 nM for chymotrypsin and chymase2. Cathepsin G Ki=0.15 μM.3 Consists of a mixture of type A (L-Leu), B (L-Val) and C (L-Ile) forms.1 Decreases plasma and tissue levels of angiotensin II without lowering mean blood pressure in a hypertensive rat model.4 Commonly used in lysis buffers to prevent degradation of proteins. Typical working concentration is 6-60 µg/ml.
Biochemicals & reagents
9076-44-2
1) Umezawa et al. (1970), Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes; J. Antibiot.(Tokyo) 23 425 2) Johnson et al. (1998), Inactivation of chymotrypsin and human skin chymase: kinetics of time-dependent inhibition in the presence of substrate; Biochim.Biophys.Acta 953 269 3) Stein and Strimpler (1987), Slow-binding of chymotrypsin and cathepsin G by the peptide aldehyde chymostatin; Biochemistry 26 2611 4) Roszkowska-Chojecka et al. (2015), Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat; Exp. Physiol. 100 1093
-20°C
TARGET: Protease -- PATHWAY: Degradation -- DISEASE AREA: Hypertension